Short-course adjuvant trastuzumab will increase cure rates in patients with human epidermal growth factor receptor 2-positive breast cancer

S Afr Med J. 2017 Jul 28;107(8):654-655. doi: 10.7196/SAMJ.2017.v107i8.12673.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Breast Neoplasms*
  • Humans
  • Receptor, ErbB-2*
  • Trastuzumab

Substances

  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab